INTRODUCTION
============

Holoprosencephaly (HPE) is characterized by failure to define the midline of the embryonic forebrain and/or midface and is one of the most common human birth defects ([@b7-0040368]; [@b14-0040368]; [@b36-0040368]; [@b54-0040368]). Clinical presentation of HPE is remarkably variable, and the range of defects extends from most to least severe in a continuum known as the HPE spectrum. Based on the degree of midline cleavage of the telencephalon, classical HPE is commonly classified into three categories ([@b7-0040368]; [@b36-0040368]). The most severe form, alobar HPE, is characterized by a complete failure to divide the forebrain into left and right hemispheres; semilobar and lobar HPE are progressively less severe subtypes. Craniofacial midline anomalies range from cyclopia with proboscis in the most severe cases to single nostril, cleft lip and palate, hypotelorism (close-spaced eyes) and solitary median maxillary central incisor in milder cases ([@b7-0040368]; [@b36-0040368]). Mild facial midline abnormalities can occur in the absence of brain malformations and are sometimes called microforms of HPE.

The etiology of HPE is heterogeneous, with both genetic and environmental causes ([@b8-0040368]; [@b12-0040368]; [@b14-0040368]; [@b27-0040368]; [@b34-0040368]). Non-syndromic HPE occurs in both inherited (familial) and sporadic forms, and nine genes have been linked to the former and/or the latter: *SHH*, *ZIC2*, *SIX3*, *TGIF*, *PTCH1*, *GLI2*, *TDGF1*, *FOXH1* and *DISP1* ([@b12-0040368]; [@b14-0040368]). All mutations are found in the heterozygous state and are usually loss-of-function mutations, although some might possess dominant-negative properties ([@b11-0040368]; [@b44-0040368]; [@b45-0040368]; [@b48-0040368]). The extensive phenotypic variability that characterizes human HPE is seen in both sporadic cases and within pedigrees; in the latter, more than one-third of mutation carriers are without clinical expression ([@b6-0040368]; [@b34-0040368]). These observations suggest that heterozygous mutation of HPE genes might be insufficient to produce severe anomalies and that HPE arises from a complex interplay of developmental, genetic and environmental factors ([@b27-0040368]; [@b34-0040368]). Potential explanations include: (1) multiple genetic-hit models, such as heterozygous mutation of two HPE genes (digenic mutation) or interaction between mutation of an HPE gene and otherwise silent modifier genes; (2) environmental insults during specific stages of fetal development, with timing of the insult dictating severity of outcome; (3) stochastic events within a halpoinsufficient HPE gene background; and (4) gene-environment interactions ([@b27-0040368]).

Disruption of sonic hedgehog (SHH) signaling is a major common theme in the development of HPE. Studies with model organisms demonstrate that Shh produced by the prechordal mesendoderm (PCM) is required for initiating development of the midline of the forebrain and midface ([@b26-0040368]; [@b35-0040368]; [@b36-0040368]; [@b47-0040368]). This occurs by a progressive mechanism whereby Shh produced by one midline structure induces *Shh* expression in a successive midline structure. Shh produced by the PCM induces expression of pathway target genes in the rostral diencephalon ventral midline of the developing forebrain, including *Ptch1*, *Gli1* and *Shh* itself ([@b3-0040368]; [@b10-0040368]; [@b15-0040368]; [@b29-0040368]; [@b33-0040368]; [@b47-0040368]). Shh produced by the rostral diencephalon ventral midline is required for maintenance of *Fgf8* expression in the rostral commissural plate ([@b2-0040368]; [@b39-0040368]). Shh and Fgf8, in conjunction with dorsally derived bone morphogenic proteins (BMPs), ultimately dictate dorsoventral patterning, cell proliferation and cell death in the developing forebrain ([@b13-0040368]; [@b39-0040368]; [@b53-0040368]). As embryogenesis proceeds, Shh produced by the forebrain induces expression of *Shh* in the ectoderm of the frontonasal and maxillary processes of the developing face. Shh produced by these latter two structures patterns neural-crest-derived facial primordia to produce specific cartilaginous structures and bones of the craniofacial midline ([@b19-0040368]; [@b20-0040368]; [@b21-0040368]; [@b29-0040368]). Most human HPE genes are either components of the SHH pathway, or directly or indirectly affect SHH expression in either the PCM or the developing ventral forebrain ([@b12-0040368]; [@b14-0040368]; [@b19-0040368]; [@b20-0040368]; [@b21-0040368]; [@b29-0040368]).

Shh activates a conserved signal transduction pathway in which binding of Shh to its membrane receptor Patched1 (Ptch1) results in signaling by a second membrane protein, Smoothened (Smo) and induction of pathway target genes via the Gli family of transcription factors ([@b24-0040368]; [@b52-0040368]). The levels and activity of Shh are tightly regulated, in part via a feedback network that acts at the level of ligand binding ([@b25-0040368]). Ptch1 and another cell surface protein, Hhip1, are induced by Shh signaling, and each binds and sequesters Shh, consequently limiting the magnitude and range of signaling ([@b23-0040368]). Cdo (also called Cdon) and Boc are closely related cell surface IgSF proteins that display an opposite pattern: they bind Shh and promote signaling, but their expression is often negatively regulated by pathway activity ([@b51-0040368]; [@b55-0040368]; [@b56-0040368]).

Mice lacking Cdo display HPE with strain-specific severity ([@b9-0040368]; [@b56-0040368]). On a 129S6/SvEvTac (129) background, ∼30% of *Cdo^--/−^* mice have mild facial microforms of HPE. On a C57BL/6NTac (B6) background, ∼80% of *Cdo^--/−^* mice have a more severe phenotype, including semi-lobar HPE and a single nostril. These results provide strong support for the notion that silent modifier genes contribute to the variability of the HPE spectrum ([@b27-0040368]; [@b56-0040368]). *Cdo* and *Boc* are expressed at high levels in dorsal regions of the developing CNS, with ventral expression inhibited by Shh signaling itself ([@b37-0040368]; [@b38-0040368]; [@b51-0040368]). *Cdo* is expressed at low levels in the PCM but not in the ventral forebrain, whereas *Boc* is expressed at low levels in the ventral forebrain ([@b37-0040368]; [@b38-0040368]; [@b51-0040368]; [@b56-0040368]). Expression of *Shh* in the PCM of B6.*Cdo^--/−^* mice is not obviously perturbed, but HPE in *Cdo^--/−^* mice on this background is accompanied by diminished expression of *Shh* and Shh target genes in the developing ventral diencephalon and telencephalon ([@b56-0040368]). These results argue that loss of Cdo results in disruption of Shh signaling in and/or from the PCM, with consequent effects on forebrain and facial patterning. Mice homozygous for a strongly hypomorphic *Boc* allele have defects in Shh-mediated guidance of commissural axons ([@b40-0040368]). Mice with mutations of *Cdo* or *Boc* therefore have limited and specific loss-of-Shh-function phenotypes. It has recently been demonstrated that combined genetic removal of the two *Drosophila* orthologs of *Cdo* and *Boc*, called *Ihog* and *Boi*, results in a phenotype similar to that of *Hedgehog* (*Hh*) mutants, revealing that these factors are essential but redundant components of the Hh pathway in the fruit fly ([@b4-0040368]; [@b58-0040368]).

We report here construction of a targeted, null *Boc* allele and analysis of *Cdo;Boc* double mutants on the 129 background. *Cdo^--/−^;Boc^--/−^* animals display lobar HPE with strong craniofacial anomalies, but partitioning of the forebrain into hemispheres occurs. This is accompanied by reduced expression of *Shh* and pathway target genes in the developing ventral forebrains of such mice at specific stages. Boc therefore functions as a spatiotemporal modifier of HPE phenotypes associated with loss of its paralog, Cdo. Furthermore, Cdo and Boc have specific, selective roles in Shh signaling in mammals, because *Cdo;Boc* double-mutant mice do not display the alobar HPE or cyclopia seen in *Shh*-null mice ([@b5-0040368]), nor do they have major defects in digit patterning or development of vertebrae, which are also Shh-dependent processes ([@b33-0040368]). This is in contrast to the essential role of Ihog and Boi in Hh signaling in the fruit fly and indicates that mammalian development entails additional factors and/or distinct mechanisms at this level of regulation of the Hh pathway.

RESULTS
=======

*Boc*^--/−^ mice are viable and do not display HPE phenotypes
-------------------------------------------------------------

To identify developmental functions of Boc in the mouse, gene targeting in embryonic stem (ES) cells was used to disrupt the *Boc* gene. The targeting strategy produced two different alleles ([Fig. 1A](#f1-0040368){ref-type="fig"}--C). *Boc^AP-1^* has a deletion of the first coding exon (which encodes the start codon and signal sequence) and an insertion of a cassette containing a selectable marker and an IRES human placental alkaline phosphatase reporter gene in the second coding exon; *Boc^AP-2^* contains only the insertion. No Boc protein was observed in western blot analyses of embryos from mice homozygous for either allele, suggesting they are likely to be null ([Fig. 1D](#f1-0040368){ref-type="fig"}). Embryos carrying either allele displayed alkaline phosphatase activity in a pattern that mirrored the one seen with RNA in situ hybridization with probes against *Boc* (shown in [Fig. 1E](#f1-0040368){ref-type="fig"} for *Boc^AP-1^* at E11.5) ([@b38-0040368]). *Boc^AP-1/AP-1^* and *Boc^AP-2/AP-2^* mice had similar phenotypes and were used interchangeably in this study. The mutant alleles are referred to collectively as *Boc^−^* for convenience.

*Boc^+/−^* mice were interbred, and offspring were genotyped at postpartum day 10 (P10). All three genotypes (*Boc*^+/+^, *Boc^+/−^* and *Boc^--/−^*) were detected at the expected mendelian ratios in both a mixed 129×B6 background and a congenic 129 background. *Boc^--/−^* animals were viable and did not display HPE-related phenotypes.

![**Boc mutant mice are viable.** (A) Strategy for targeted mutagenesis of the *Boc* locus via homologous recombination. The wild-type allele (*Boc*), targeting vector and resulting targeted alleles (*Boc^AP-1^* and *Boc^AP-2^*) are shown with relevant restriction sites and exons (black boxes). *Boc^AP-1^* and *Boc^AP-2^* were generated by homologous recombination at one of two regions of homology present in the 5′ end of the targeting vector (designated crossover points C1 and C2, respectively); the 3′ crossover point (C3) is the same for both alleles. Note that *Boc^AP-1^* deletes exon 1 and contains an insertion of a human alkaline phosphatase (AP) reporter gene \[under the control of an internal ribosome entry site (IRES); not shown\] linked to a *PGK-Neo* selectable marker gene. *Boc^AP-2^* contains only the insertion. (B) Genotype analysis of ES cell clones by Southern blot. Lane numbers represent ES clone numbers, and bands corresponding to wild-type (wt), *Boc^AP-1^* and *Boc^AP-2^* alleles are indicated. (C) PCR genotyping analysis of tail DNA from offspring of intercrosses of *Boc^+/−^* animals, showing all three possible genotypes. (D) Western blot analysis of Boc expression in wild-type and mutant animals. E13.5 embryos from intercrosses of *Boc^+/AP-1^* (left panel) and *Boc^+/AP-2^* (right panel) mice were genotyped, and extracts from embryonic heads were analyzed by immunoblotting with antibodies against Boc. Genotypes are indicated above the lanes. (E) Whole E11.5 embryos of all three genotypes were stained for AP activity, which mirrors normal *Boc* expression. Notably, Boc is expressed in dorsal telencephalon (arrowhead), facial primodia (black arrow) and anterior limb buds (white arrow). Scale bar: 1 mm.](DMM005744F1){#f1-0040368}

HPE phenotypes in *Cdo*^--/−^*;Boc^+/−^* and *Cdo*^--/−^*;Boc*^--/−^ mice on a 129 background
---------------------------------------------------------------------------------------------

Because Boc and Cdo have similar (although not identical) expression patterns and both bind Shh to promote signaling, we reasoned that some aspects of their function might be redundant or compensatory, similarly to what is observed with the *Drosophila* orthologs Ihog and Boi ([@b4-0040368]; [@b58-0040368]). To evaluate this possibility, *Boc* and *Cdo* mutant mice on a 129 background were intercrossed to construct double mutants. The 129 background was chosen because *Cdo^--/−^* mice on this background are viable and display only microforms of HPE ([@b56-0040368]). Unless otherwise noted in the figures, all results are from animals of the 129 background. *Cdo^+/−^;Boc^+/−^* mice are fertile and appeared normal. These animals were intercrossed and offspring genotyped at P10. Mice of all possible genotypes were found at approximately the predicted mendelian ratio except *Cdo^--/−^;Boc^--/−^*mice, which were never recovered at P10 (supplementary material Table S1). *Cdo^--/−^;Boc^--/−^* embryos were obtained at various developmental stages, including E18.5, suggesting that these mice died perinatally and/or were selectively culled by their mothers. *Cdo^--/−^;Boc^+/−^* mice were present at slightly less than the expected frequency (supplementary material Table S1). Some embryos of this genotype (but not embryos of the *Cdo^+/−^;Boc^--/−^* genotype) had craniofacial patterning defects that were nearly as severe as *Cdo^--/−^;Boc^--/−^* embryos (vide infra), and it is therefore likely that a small fraction of *Cdo^--/−^;Boc^+/−^* mice also die perinatally.

To address whether removal of Boc enhanced phenotypes of mice lacking Cdo, craniofacial and forebrain development was analyzed in mice of various genotypes. Whole *Cdo^--/−^;Boc^--/−^* embryos at E11.5, E13.5 and E15.5 had strong midfacial HPE defects with high penetrance. At E11.5, *Cdo^--/−^;Boc^--/−^* embryos displayed hypoplasia of the facial midline with somewhat variable expressivity ([Fig. 2A](#f2-0040368){ref-type="fig"}); the most severe cases included fusion of the nasal processes ([Fig. 2Ae](#f2-0040368){ref-type="fig"}), a phenotype similar to that of *Cdo^--/−^;Shh^+/−^* embryos ([@b51-0040368]). At E13.5 and E15.5, double-mutant animals had a single pointed nostril, fused upper lip and hypotelorism ([Fig. 2B](#f2-0040368){ref-type="fig"}). *Cdo^--/−^;Boc^+/−^* embryos showed similar defects but with lower penetrance ([Table 1](#t1-0040368){ref-type="table"}). At these stages, *Boc^--/−^* embryos always resembled the wild-type, and *Cdo^--/−^* embryos displayed related but much milder phenotypes at low frequency ([@b56-0040368]) (our unpublished results). E18.5 cranial bone and cartilage preparations revealed that, although *Boc^--/−^* and *Cdo^+/−^;Boc^--/−^* embryos had normal cranial and palatal bone patterning, *Cdo^--/−^*, *Cdo^--/−^;Boc^+/−^*and *Cdo^--/−^;Boc^--/−^* embryos displayed progressively more severe midline defects in these bones, with increasing penetrance ([Fig. 3](#f3-0040368){ref-type="fig"}, [Table 1](#t1-0040368){ref-type="table"}) ([@b9-0040368]). Defects included fused premaxillary bones; dysmorphic maxillary bones with absent or diminished maxillary shelves; reduced size of the basisphenoid bone; and foramen in the basisphenoid bone. No defects of the mandible were seen in mice of any genotype studied.

![**HPE phenotypes in *Cdo*^--/−^*;Boc*^--/−^ mice on a 129 background.** (A) Frontal views of E11.5 embryos of the indicated genotypes. Note that the distance between the left and right nasal pits (denoted by brackets) is dramatically reduced but somewhat variable in *Cdo^--/−^;Boc^--/−^* embryos (panels d, e) compared with the control embryo (panel a). Scale bar: 0.5 mm. (B) Frontal views of forebrains and faces of E13.5 (upper panel) and E15.5 (lower panel) embryos of the indicated genotypes. Note that the *Cdo^--/−^;Boc^--/−^*embryos have fused nostrils (panels d, h; black arrows) and upper lip (panels d, h; red arrows) but display separation of the left and right forebrain hemispheres. A higher magnification view of the E13.5 *Cdo^--/−^;Boc^--/−^*embryo highlights the defects. Scale bars: 1 mm; 0.25 mm for enlargement. (C) H&E staining of frontal forebrain sections of E13.5 embryos. *Cdo^--/−^;Boc^--/−^*embryos display lobar HPE as indicated by continuity across the ventral midline (panels d, e; red arrows) and reduced medial ganglionic eminences. M, medial ganglionic eminence; L, lateral ganglionic eminence. Scale bar: 0.5 mm. (D) In situ hybridization analysis of *Ptch1* (middle panel) and *Nkx2.1* (lower panel) expression, revealing diminished expression in *Cdo^--/−^;Boc^--/−^* embryos. Scale bars: 0.5 mm.](DMM005744F2){#f2-0040368}

Somewhat surprisingly, double-mutant embryos had relatively mild ventral forebrain midline defects, which were similar to lobar HPE. Frontal sections of E13.5 forebrains revealed that, although *Cdo^--/−^* and *Boc^--/−^* mice had normally patterned forebrains, *Cdo^--/−^;Boc^--/−^* embryos displayed continuity across the ventral midline, and medial and lateral ganglionic eminences that were either reduced in size or, occasionally, fused ([Fig. 2C](#f2-0040368){ref-type="fig"}). Accordingly, expression of the direct Shh pathway target genes *Ptch1* and *Nkx2.1* was reduced in the ventral forebrains of E13.5 *Cdo^--/−^;Boc^--/−^*embryos ([Fig. 2D](#f2-0040368){ref-type="fig"}). The reduction in *Ptch1* and *Nkx2.1* expression was not simply a consequence of loss of ventral forebrain structure, because the embryos shown here ([Fig. 2Dd,h](#f2-0040368){ref-type="fig"}) did not have the most severe phenotype observed and had defined medial ganglionic eminences.

Expression of *Shh* and *Fgf8* correlates with the strain-dependent severity of forebrain and facial HPE phenotypes in mice lacking Cdo and/or Boc
--------------------------------------------------------------------------------------------------------------------------------------------------

*Fgf8* expression in the commissural plate is initiated independently of Shh at E8.5, but by E9.0 its maintenance requires Shh produced by the ventral forebrain ([@b39-0040368]). *Shh*^--/−^ embryos have the most severe form of HPE, and *Fgf8* hypomorphs are also holoprosencephalic ([@b5-0040368]; [@b50-0040368]). Furthermore, Fgf signaling is downstream of Shh signaling in midline patterning, and at least some of the midline defects in Shh-deficient mice are likely caused by abnormal Fgf signaling ([@b17-0040368]; [@b41-0040368]). *Shh* expression is delayed and reduced in the ventral forebrain of E8.75--E9.5 *Cdo^--/−^* embryos on the B6 background, and *Fgf8* expression is strongly diminished in the commissural plate of such embryos at E9.0--E9.5, which is consistent with their HPE phenotype ([@b56-0040368]). Similarly to *Shh^--/−^* embryos, E8.5 B6.*Cdo^--/−^* embryos initiated *Fgf8* expression properly ([Fig. 4A](#f4-0040368){ref-type="fig"}), despite the subsequent failure to maintain expression ([@b56-0040368]). Therefore, the defect in *Fgf8* expression at E9.0 in B6.*Cdo^--/−^* embryos is consistent with loss of Shh pathway activity.

###### 

Frequency of craniofacial defects in 129.*Cdo^--/−^;Boc^+/−^* and 129.*Cdo^--/−^;Boc^--/−^* mice

![](DMM005744T1)

To gain insight into the differential strain sensitivity of *Cdo^--/−^*mice, as well as into the genetic interaction between *Cdo* and *Boc*, *Shh* and *Fgf8* expression were analyzed at E9.5 in *Cdo* and *Boc* single- and double-mutant embryos on the 129 background. The pattern of *Shh* and *Fgf8* expression in the ventral forebrain of 129.*Cdo^--/−^* and 129.*Boc^--/−^* was similar to that of control embryos ([Fig. 4Ba--c,Ca--c](#f4-0040368){ref-type="fig"}). The level of *Shh* expression in 129.*Cdo^--/−^;Boc^--/−^*embryos was clearly lower than in controls in the ventral telencephalon but, unlike B6.*Cdo^--/−^* embryos ([@b56-0040368]), expression extended anterior to the developing eye ([Fig. 4Bd](#f4-0040368){ref-type="fig"}). Also unlike B6.*Cdo^--/−^* embryos ([@b56-0040368]), 129.*Cdo^--/−^;Boc^--/−^*embryos expressed *Fgf8* in the commissural plate at this stage ([Fig. 4Cd](#f4-0040368){ref-type="fig"}). These results suggest that a threshold level of *Shh* expression in the anterior ventral forebrain is required to maintain *Fgf8* expression in the commissural plate, and strain 129 mice maintain such a level even in the absence of both Cdo and Boc, whereas B6 mice fail to maintain this threshold amount in the absence of Cdo alone. As *Fgf8* hypomorphs are themselves holoprosencephalic and Fgf proteins act downstream of Shh in this system ([@b17-0040368]; [@b41-0040368]; [@b50-0040368]), differential *Fgf8* expression might be sufficient to explain the varying severity of forebrain phenotypes seen in B6.*Cdo^--/−^* embryos (incomplete cleavage) and 129.*Cdo^--/−^;Boc^--/−^* embryos (cleavage occurs; lobar HPE-type ventral midline defects).

The development of the forebrain and face are intimately connected, because the forebrain secretes signaling molecules that help pattern the face and also provides a supporting structure on which the face develops ([@b29-0040368]). 129.*Cdo^--/−^;Boc^--/−^*embryos show craniofacial defects that are more severe than those in B6.*Cdo^--/−^* embryos, but the 129.*Cdo^--/−^;Boc^--/−^* embryos show a milder forebrain midline defect than B6.*Cdo^--/−^* embryos, which is an unusual phenotype. As shown above, 129.*Cdo^--/−^;Boc^--/−^* embryos expressed *Shh* in a more rostral forebrain domain than did B6.*Cdo^--/−^* embryos ([@b56-0040368]), and this was accompanied by *Fgf8* expression in the former but not latter animals ([@b56-0040368]) ([Fig. 4](#f4-0040368){ref-type="fig"}). Although this might explain the milder forebrain phenotype in 129.*Cdo^--/−^;Boc^--/−^* embryos, it is less consistent with the more severe facial defects seen in these mice, relative to the B6.*Cdo^--/−^* embryos. We therefore analyzed expression of *Shh* and Shh target genes, including *Fgf8*, in the ventral forebrain at E10.5, a stage at which the forebrain is involved in patterning of the midface.

![**Cranial bone defects in *Cdo*^--/−^*;Boc*^--/−^embryos.** Ventral views of cranial bone preparations of E18.5 embryos stained with Alizarin Red and Alcian Blue for bone and cartilage, respectively. Mandibles have been removed for visualization of the palate. Some *Cdo^--/−^;Boc*^+/+^ embryos have cranial bone defects including fused premaxillary bones (c; white arrow), missing premaxillary shelves, dysmorphogenesis of the maxillary bones and underdeveloped maxillary shelves (c; white asterisk). *Cdo^--/−^;Boc^+/−^* and *Cdo^--/−^;Boc^--/−^*embryos also show fused premaxillary bones (e--h; white arrows), as well as more severe cranial bone defects than *Cdo^--/−^;Boc*^+/+^ embryos, in a *Boc* dosage-dependent manner. These latter defects include open palatal processes of the palatine bones (f; red asterisk), highly dysmorphic maxillary bones (e,g,h; red arrows), and underdeveloped basisphenoid bones (f,h; red arrowheads). The larger image in the lower right corner (a') is an enlargement of the control *Cdo^+/−^;Boc^+/−^*preparation (a) for the purpose of labeling structures. PM, premaxillary bone; M, maxillary bone; MS, maxillary shelves; PP, palatal process of the palatine; PS, premaxillary shelves; BS, basisphenoid bone; BO, basioccipital bone. Scale bar: 1 mm.](DMM005744F3){#f3-0040368}

![**Expression of *Shh* and *Fgf8* correlate with the strain-dependent severity of forebrain phenotypes in *Cdo* and *Boc* mutants.** (A--C) Whole-mount RNA in situ hybridization analyses. (A) *Fgf8* expression in E8.75 *Cdo*^+/+^ and *Cdo^--/−^* embryos on a B6 background. Note that *Fgf8* expression is induced properly in the *Cdo^--/−^* embryo in both the anterior neural ridge (arrow) and isthmus (arrowhead). Scale bar: 0.5 mm. (B) Lateral view of *Shh* expression in E9.5 embryos of the indicated genotype on a 129 background. Note that *Shh* is expressed in the ventral telencephalon of the *Cdo^--/−^;Boc^--/−^*embryo (d, arrow) but signal strength is reduced compared with the control embryo (a). Scale bar: 0.2 mm. (C) Lateral view of *Fgf8* expression in E9.5 embryos of the indicated genotype on a 129 background. Note that *Fgf8* is expressed in the commissural plate of the *Cdo^--/−^;Boc^--/−^* embryo (d; arrow). Scale bar: 0.2 mm.](DMM005744F4){#f4-0040368}

At E10.5, *Shh* expression in the ventral telencephalon was almost completely absent in *Cdo^--/−^;Boc^--/−^* embryos ([Fig. 5A](#f5-0040368){ref-type="fig"}). Similarly, expression of *Fgf8* and *Nkx2.1* at E10.5 was also strongly reduced in the rostral midline of these mice ([Fig. 5D,E](#f5-0040368){ref-type="fig"}). This progressive temporal reduction in *Shh* and *Fgf8* expression in the double mutants correlates with the roles of these factors in facial patterning, and *Cdo* and *Boc* appear to cooperate to regulate their expression in this process. Despite the reduction in *Shh* and *Fgf8* expression, expression of *Ptch1* and *Gli1* was not dramatically altered in the ventral forebrains of double mutants at this stage ([Fig. 5B,C](#f5-0040368){ref-type="fig"}). To apply a more quantitative approach to these results, RNA was extracted from dissected heads of E10.5 control and *Cdo^--/−^;Boc^--/−^* embryos, and quantitative RT-PCR (qPCR) was performed. mRNA levels of *Shh*, *Fgf8* and *Nkx2.1* were each significantly reduced in the *Cdo^--/−^;Boc^--/−^* embryonic heads ([Fig. 6](#f6-0040368){ref-type="fig"}); in similar analyses, *Ptch1* and *Gli1* mRNA levels were not significantly different between control and double-mutant embryos (data not shown). It is likely that the qPCR results underestimate the reduction in expression of these genes in the most affected region of *Cdo^--/−^;Boc^--/−^* embryos (the rostroventral midline) because more caudal structures where changes in expression are not obvious were by necessity included in the dissected embryos.

Palatogenesis defects in mice lacking Cdo and Boc
-------------------------------------------------

Palatogenesis is regulated by Shh signaling and defects in secondary palate formation sometimes present as part of the HPE spectrum ([@b16-0040368]; [@b36-0040368]). Analysis of E17.5 embryos showed that although *Cdo^--/−^*, *Boc^--/−^* and *Cdo^+/−^;Boc^--/−^*embryos had normal secondary palates, *Cdo^--/−^;Boc^+/−^* and *Cdo^--/−^;Boc^--/−^* embryos had malformations of the secondary palate, including in some cases a cleft ([Fig. 7A](#f7-0040368){ref-type="fig"} and [Table 1](#t1-0040368){ref-type="table"}). Furthermore, the primary palates of one *Cdo^--/−^;Boc^+/−^* and both *Cdo^--/−^;Boc^--/−^*embryos were misshapen ([Fig. 7A](#f7-0040368){ref-type="fig"}).

The secondary palate arises from the medial sides of the maxillary processes flanking the embryonic oral cavity. Development of the secondary palate involves vertical growth of palatal shelf primordia into the oral cavity, along the sides of the developing tongue. At E14.0, the bilateral palatal shelves elevate to a horizontal position above the tongue and grow toward each other. At E14.5, the opposing palatal shelves then adhere along their medial edge epithelia to create a transient medial epithelial seam (MES), which starts to disappear at E15.5. At E16.5, the MES disappears completely to form the intact secondary palate, which separates the nasal cavity from the oral cavity, a condition that is required for simultaneous breathing and feeding. Disturbance of any of these processes can result in palate defects.

![**Reduction of *Shh* signaling in the ventral forebrain and facial primodia of 129.*Cdo*^--/−^*;Boc*^--/−^embryos at E10.5.** (A--D) Whole-mount RNA in situ hybridization analyses. (A) Lateral and ventral views of *Shh* expression in the ventral forebrain and facial epithelium of E10.5 embryos of the indicated genotype on a 129 background. Note the dramatic reduction of *Shh* expression in the ventral forebrain of the *Cdo^--/−^;Boc^--/−^* embryo (denoted by the bracket, telencephalon indicated with an arrow). Scale bars: 0.5 mm (lateral); 0.2 mm (ventral). (B) Lateral and ventral views of *Ptch1* expression in the ventral forebrain and facial epithelium of E10.5 embryos of the indicated genotype on a 129 background. Scale bars: 0.5 mm (lateral); 0.2 mm (ventral). (C) Lateral and ventral views of *Gli1* expression in the ventral forebrain of E10.5 embryos on a 129 background. Scale bars: 0.5 mm (lateral); 0.2 mm (ventral). (D) Ventral view of *Fgf8* expression in commissural plates of E10.5 embryos on a 129 background. The head of the *Cdo^--/−^;Boc^--/−^*embryo is smaller than the control *Cdo^+/−^;Boc^+/−^*embryo but was alive, and the two embryos were of similar somite number and size (supplementary material Fig. S1). Scale bar: 0.5 mm. (E) Frontal view of *Nkx2.1* expression in E10.5 embryos on a 129 background. Scale bar: 0.5 mm.](DMM005744F5){#f5-0040368}

*Cdo;Boc* double-mutant embryos were analyzed at different stages of palatogenesis. Because a range of phenotypes was observed in these embryos, three different double mutants are presented at each stage. At E13.5, control embryos showed two vertically oriented palatal shelves ([Fig. 7Ba](#f7-0040368){ref-type="fig"}). In double-mutant embryos, the shelves appeared to have initiated properly, but vertical growth was abnormal; instead of growing downward alongside the tongue, the palatal shelves usually grew medially towards each other ([Fig. 7Bc,d](#f7-0040368){ref-type="fig"}). At E14.5, the control palatal shelves had elevated into a horizontal position above the tongue and came into contact to form the MES ([Fig. 7Be](#f7-0040368){ref-type="fig"}). In *Cdo;Boc* double-mutant embryos, in most cases, the palatal shelves either resembled those at E13.5 ([Fig. 7Bf](#f7-0040368){ref-type="fig"}) or, if some degree of growth had occurred by this stage, failed to elevate and form a MES ([Fig. 7Bg](#f7-0040368){ref-type="fig"}). In a milder case, as shown in [Fig. 6Bf](#f6-0040368){ref-type="fig"}, the palatal shelves showed relatively normal growth at E14.5; however, only one of the shelves had elevated normally. At this stage, it was also evident that the precartilage primordium of the nasal septum is hypoplastic in double mutants ([Fig. 7Bf,g](#f7-0040368){ref-type="fig"}). At E15.5, the control palatal shelves had already fused, and the MES had started to disappear ([Fig. 7Bi](#f7-0040368){ref-type="fig"}). The double-mutant palatal shelves had also begun to fuse with each other but, rather than fusing at the tips of the elevated palatal shelves as normally occurs, the mutant shelves appeared to fuse medially([Fig. 7Bk](#f7-0040368){ref-type="fig"} and [7Bl](#f7-0040368){ref-type="fig"}). In a milder case, where the palatal shelves had elevated appropriately, the tips of the shelves failed to fuse because they did not align properly for fusion to occur ([Fig. 7Bj](#f7-0040368){ref-type="fig"}).

![**qPCR analysis of *Shh*, *Fgf8* and *Nkx2.1* expression in control and *Cdo*^--/−^*;Boc*^--/−^ embryonic heads at E10.5.** (A) *Shh* expression. (B) *Fgf8* expression. (C) *Nkx2.1* expression. Signals were normalized to *Gapdh* expression, which was the same in all embryos, and the mean values for control embryos were set to 1.0. Control embryos were of the *Cdo*^+/+^*;Boc^+/−^, Cdo^+/−^;Boc*^+/+^ or *Cdo^+/−^;Boc^+/−^*genotypes. \**P*\<0.05 in Student's *t-*test, *n*≥3 embryos.](DMM005744F6){#f6-0040368}

Palatogenesis is dependent on SHH signaling, and cleft palate has been observed in human HPE associated with *SHH* mutations ([@b16-0040368]; [@b36-0040368]). Analysis of mice in which *Shh* is conditionally removed from the palatal shelf epithelium, or *Smo* is conditionally removed from the palatal mesenchyme, demonstrated that Shh signals directly from the epithelium to the mesenchyme to promote outgrowth of the palatal shelves; such mice have cleft palate ([@b28-0040368]; [@b43-0040368]). Consistent with the notion that Shh signaling is diminished during palatogenesis in *Cdo^--/−^;Boc^--/−^* embryos, expression of *Ptch1* in the palatal shelves of E13.5 double-mutant mice was reduced compared with levels in control animals ([Fig. 7Ca vs 7Cb](#f7-0040368){ref-type="fig"} and [7Cc](#f7-0040368){ref-type="fig"}). The reduction in *Ptch1* expression was not simply a consequence of abnormal development, because a palate from a *Cdo^--/−^;Boc^--/−^* embryo that was relatively normally patterned ([Fig. 7Cb](#f7-0040368){ref-type="fig"}) also displayed diminished *Ptch1* signal.

![***Cdo*^--/−^*;Boc*^--/−^ mice display defects in palatogenesis.** (A) Ventral views of E17.5 palates of embryos of the indicated genotype on a 129 background. Lower jaws have been removed for visualization of palates. PP, primary palate; SP, secondary palate. Black arrows indicate an open palate in *Cdo^--/−^;Boc^+/−^* and *Cdo^--/−^;Boc^--/−^* embryos (f,h). The red arrow indicates abnormal rugae in the secondary palate of a *Cdo^--/−^;Boc^--/−^* embryo (g). The red arrowheads indicate misshapen primary palates in *Cdo^--/−^;Boc^+/−^* and *Cdo^--/−^;Boc^--/−^* embryos (e--h). Scale bar: 1 mm. (B) H&E staining of palate sections from E13.5, E14.5 and E15.5 embryos of a control embryo and three different *Cdo^--/−^;Boc^--/−^* embryos; note that the double-mutant embryos display various palatogenesis defects. See text for detailed description. ps, palatal shelves; T, tongue; asterisk, molar; arrow in e indicates the medial epithelial seam (MES). Scale bars: 0.5 mm. (C) RNA in situ hybridization of *Ptch1* expression in E13.5 palate sections. Scale bar: 0.5 mm.](DMM005744F7){#f7-0040368}

*Cdo*^--/−^*;Boc*^--/−^ mice do not display significant defects in limb and axial skeleton development
------------------------------------------------------------------------------------------------------

*Cdo* and *Boc* are both expressed in the anterior two-thirds of the limb bud mesenchyme, with expression excluded from the posterior region, including the zone of polarizing activity (ZPA), because of Shh-mediated repression of expression of these genes ([@b37-0040368]; [@b38-0040368]; [@b51-0040368]). Although *Shh^--/−^*mice have severe defects of the limbs and digits ([@b33-0040368]), *Cdo^--/−^* mice display normal limb and digit patterning, even on the sensitized B6 background ([@b5-0040368]; [@b56-0040368]). We speculated that the reason that *Cdo^--/−^* animals showed normal limb and digit formation was that Boc had a redundant or compensatory role in this process. However, analysis of *Cdo^--/−^;Boc^--/−^* embryos revealed that they also had normal limbs and digits ([Fig. 8A](#f8-0040368){ref-type="fig"}).

![**Limb, digit and cervical vertebrae development in *Cdo*^--/−^*;Boc*^--/−^mice.** (A) Whole E15.5 *Cdo^+/−^;Boc^+/−^* (control, a) and *Cdo^--/−^;Boc^--/−^* embryos (f) and their four limbs (b--e and g--j). RF, right forelimb; LF, left forelimb; RH, right hindlimb; and LH, left hindlimb. Scale bars: 1 mm. (B) Frontal view of cervical vertebrae of E18.5 mice of the indicated genotype. Note the lack of ossification of intervertebral disks in the *Cdo^--/−^;Boc^--/−^* embryo (arrow). Scale bar: 1 mm.](DMM005744F8){#f8-0040368}

Shh is also required for formation of the axial skeleton, including vertebrae and ribs ([@b33-0040368]). Skeletal preparations of E18.5 embryos revealed that cervical vertebrae were largely normal in *Cdo^--/−^;Boc^--/−^* embryos, although they lacked ossification of intervertebral discs ([Fig. 8B](#f8-0040368){ref-type="fig"}). Rib development was also normal in double-mutant embryos (data not shown). Therefore, similarly to limb and digit patterning, development of the axial skeleton occurs without major disruption in the absence of Cdo and Boc.

That 129.*Cdo^--/−^;Boc^--/−^* mice displayed neither the most severe HPE phenotypes seen in *Shh*-null mice, nor major defects in limb and axial skeleton development, is distinct from the situation in *Drosophila*, where Ihog and Boi are essential but redundant for Hh pathway activity ([@b4-0040368]; [@b58-0040368]). One possible mitigating factor is the 129 genetic background, which is largely resistant to HPE phenotypes induced by genetic removal of *Cdo* ([@b56-0040368]). To assess this possibility, *Boc^+/−^* mice were back-crossed onto the B6 background. *Boc^--/−^* animals on this background were viable and had a normal exterior appearance at E14.5, lacking HPE and digit phenotypes (data not shown). B6.*Cdo^+/−^;Boc^+/−^* mice were then generated and intercrossed to produce double-mutant mice on this sensitive background. B6.*Cdo^--/−^;Boc^--/−^* mice had a range of HPE phenotypes, including a proboscis-like nose and hypotelorism; they also had cleft lip, a trait not seen in single mutants on either background or double mutants on the 129 background (supplementary material Fig. S2). However, even B6 double mutants did not have cyclopia or defects in digit patterning (supplementary material Fig. S2). Therefore, although the genetic background can modify the phenotype of *Cdo;Boc* double mutants, it is not sufficient to explain the incomplete loss of Shh activity in the absence of all Cdo family function.

DISCUSSION
==========

We report here analysis of mice lacking the related Shh pathway regulators Cdo and Boc; this is the first report of a vertebrate model lacking function of all Cdo/Ihog family members. The phenotypes of mice deficient in either gene singly or the two together have implications for the common birth defect HPE and provide insight into evolutionary differences in the Hh pathway between insects and mammals.

*Boc* is a silent HPE modifier gene in mice
-------------------------------------------

Human HPE is associated with heterozygous mutations in genes that encode components of the SHH pathway or regulators of *SHH* expression in the rostroventral midline. However, the observations that many carriers of such mutations are without clinical phenotype and that heterozygous mutations in these genes do not generally produce HPE in model organisms (such as mice), has led to the notion that HPE arises as a consequence of several genetic and/or environmental insults ([@b27-0040368]; [@b34-0040368]). We have previously reported that mice lacking Cdo display HPE with strain-dependent severity: *Cdo^--/−^* mice on a 129 background have facial microforms of HPE with low penetrance, whereas *Cdo^--/−^* mice on a B6 background have semilobar HPE with high penetrance ([@b56-0040368]). Therefore, strain-specific silent modifier genes determine the penetrance and expressivity of HPE in *Cdo* mutant mice. Furthermore, it is likely that modifier alleles of this type have a similar role in the human HPE spectrum ([@b27-0040368]; [@b46-0040368]). The modifier loci involved in the differential sensitivity of 129 versus B6 mice to HPE are not known, and such alleles have not yet been identified in human HPE. *Boc^--/−^* mice do not display HPE phenotypes, yet genetic removal of *Boc* strongly enhances such phenotypes in *Cdo^--/−^* mice, in a *Boc* gene dosage-sensitive manner. Therefore, *Boc* functions as a silent HPE modifier gene in mice and might have a similar role in humans, because numerous human *BOC* single-nucleotide polymorphisms (SNPs) are reported in the NCBI database, including missense and frame-shift changes (<http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=91653>). Although *Boc* might contribute to the differential sensitivity of 129 and B6 mice to loss of *Cdo* (and other HPE genes) ([@b15-0040368]; [@b42-0040368]), it is very unlikely to be the major modifier gene in this system because B6.*Cdo^--/−^* mice (which express *Boc*) have a more severe forebrain phenotype than 129.*Cdo^--/−^;Boc^--/−^*mice. Therefore, additional modifiers remain to be identified.

*Cdo* is expressed at low levels in the PCM but not in the developing ventral forebrain ([@b37-0040368]; [@b38-0040368]; [@b51-0040368]; [@b56-0040368]). The PCM is required for induction of the ventral forebrain and subsequent patterning of the forebrain and midfacial midline. The PCM serves as a source of Shh in this process, but Shh is also required for normal development of the PCM itself ([@b3-0040368]; [@b36-0040368]; [@b47-0040368]). Although we did not observe obvious defects in the PCM of B6.*Cdo^--/−^* mice ([@b56-0040368]), the lack of *Cdo* expression in the developing ventral forebrain (the affected structure) argues that loss of *Cdo* function in the PCM is the likely cause of HPE in B6.*Cdo^--/−^* mice ([@b56-0040368]). Mice that lack Boc do not display HPE, despite the fact that, similarly to Cdo, Boc binds Shh and promotes Shh signaling ([@b40-0040368]; [@b51-0040368]; [@b56-0040368]). Unlike Cdo, *Boc* is expressed in the ventral forebrain ([@b38-0040368]; [@b40-0040368]) and transiently at low levels in the PCM (unpublished results). It is possible that the genetic interaction between *Cdo* and *Boc* in the production of HPE in mice arises from a combination of loss of *Cdo* function in the PCM and *Boc* function in the PCM and/or developing ventral forebrain. *Cdo* and *Boc* are also both expressed in the developing facial mesenchyme ([@b37-0040368]; [@b38-0040368]), and this might also contribute to HPE phenotypes. Conditional removal of these factors from specific structures will be required to definitively address this point.

The reduction of expression of *Shh* and pathway target genes in *Cdo^--/−^;Boc^--/−^* mice worsens between E9.5 and E10.5, revealing that *Cdo* and *Boc* are required together in these regions for robust temporal maintenance of the autoinduction system whereby Shh regulates its own expression in successive structures of the rostroventral midline. Apparently, one copy of *Cdo* is sufficient for this process to occur because we have not observed any HPE phenotypes in *Cdo^+/−^;Boc^--/−^* mice, whereas a fraction of *Cdo^--/−^;Boc^+/−^* mice do display such phenotypes. It should be noted that *Cdo* and *Boc* are coexpressed at high levels in the developing dorsal forebrain ([@b37-0040368]; [@b38-0040368]), but Shh is not required to pattern the dorsal CNS at these stages of development ([@b18-0040368]; [@b53-0040368]), and the phenotypes seen in the double-mutant mice are consistent with the view that HPE arises from defects in ventral forebrain patterning ([@b36-0040368]).

129.*Shh^+/−^* and 129.*Boc^--/−^* mice do not have HPE, yet removal of one copy of *Shh* or dosage-dependent loss of *Boc* each synergize with loss of *Cdo* on the 129 background to produce HPE spectrum phenotypes ([@b51-0040368]) (and this study). These results, plus the fact that B6.*Cdo^--/−^* mice have semi-lobar HPE with high penetrance, suggest that 129.*Cdo^--/−^* mice have a largely sub-threshold defect of Shh signaling in the rostroventral midline that renders these mice sensitive to additional, often silent, insults. Therefore, we propose that 129.*Cdo^--/−^* mice serve as a model system for testing the multifactorial hypothesis of human HPE and for identification of additional 'second hits'. Consistent with this possibility, preliminary results indicate that 129.*Cdo^--/−^* embryos are sensitized to environmental exposures implicated in HPE (unpublished results).

Evolutionary divergence in the requirement of the Hh pathway for Cdo/Ihog family members
----------------------------------------------------------------------------------------

Although Hh ligands activate a largely evolutionarily conserved signaling pathway, there are some important differences between Hh signaling mechanisms in *Drosophila* and mice (for reviews, see [@b22-0040368]; [@b24-0040368]). It was recently reported that combined genetic removal of *Ihog* and *Boi*, the *Drosophila* Cdo and Boc orthologs, results in complete loss of response to Hh ligand, including pathway target gene expression and segmental patterning ([@b4-0040368]; [@b58-0040368]). Flies carrying mutations in either gene singly are viable, so *Ihog* and *Boi* apparently provide a redundant or compensatory function in the Hh pathway. Furthermore, a complex of Ihog or Boi and Patched is required for Hh receptor function ([@b4-0040368]; [@b58-0040368]). By contrast, Cdo and Boc have specific, selective roles in Shh signaling in mammals. For example, they are obviously involved in development of the rostroventral midline, but are dispensable for digit patterning and formation of the axial skeleton, both Shh-dependent processes ([@b33-0040368]).

The results reported here therefore reveal an evolutionary divergence of the Hh pathway in its reliance on Cdo/Ihog family members. One likely explanation for this is the existence in vertebrates, but apparently not *Drosophila*, of Gas1, a Shh-binding protein that is structurally unrelated to Cdo and Boc, but which appears to function similarly to them and has an overlapping expression pattern ([@b1-0040368]; [@b25-0040368]; [@b30-0040368]). Consistent with this possibility is that, unlike *Cdo^--/−^;Boc^--/−^* mice, mice lacking Gas1 display a defect in digit patterning, although it is not as severe as that seen in *Shh^--/−^* mice ([@b1-0040368]; [@b25-0040368]; [@b30-0040368]). The existence of additional putative co-receptors might relate to a need in mammals for additional ability to modulate Shh signaling during developmental events that play out over a longer period of time and are potentially more complex than in insects. This possibility might also be relevant to the somewhat variable facial HPE phenotypes seen in 129.*Cdo^--/−^;Boc^--/−^* mice and in the differences between *Cdo;Boc* double mutants on 129 and B6 backgrounds: reliance on Gas1 as the only (known) putative co-receptor might result in somewhat variable HPE phenotypes in *Cdo;Boc* double-mutant mice, dependant on both stochastic events and genetic background. Interestingly, *Cdo;Gas1* double-mutant mice have a much more severe HPE phenotype than either single mutant ([@b1-0040368]).

A second, non-mutually exclusive explanation for the evolutionary divergence in the requirement for Cdo/Ihog proteins is that, even though all family members bind Hh ligands and promote pathway activity, Cdo and Boc might function somewhat differently than Ihog and Boi. Hh and Shh bind non-orthologous FnIII repeats in Ihog and Cdo, respectively ([@b31-0040368]; [@b32-0040368]; [@b51-0040368]; [@b55-0040368]). Additionally, Ihog and Boi cooperate with *Drosophila* Patched to produce a high-affinity Hh binding receptor complex, but there are varying reports as to whether Cdo and Ptch1 cooperate or compete in ligand binding ([@b30-0040368]; [@b32-0040368]). Therefore, reliance on Cdo/Ihog family members is not fully evolutionarily conserved, with mammalian development involving additional factors and/or distinct mechanisms at this level of regulation of the Hh pathway.

METHODS
=======

Generation of *Boc* mutant mice, *Cdo;Boc* double-mutant mice and genotyping
----------------------------------------------------------------------------

A 500 bp mouse *Boc* cDNA fragment was used to probe a mouse PAC library (RPCI21, generously provided by Jonathan Licht, Northwestern University Feinberg School of Medicine, Chicago, IL). The targeting vector was designed to delete the first coding exon and insert a 4.3kb *IRES-hAP-loxP/PGK-neo/loxP* selectable marker and reporter gene cassette (generously provided by Thomas Lufkin, Genome Institute of Singapore, Singapore) into the second coding exon. The targeting vector generated a 540 bp deletion (encompassing the entire first coding exon) by linking the 5′ flanking 6 kb *Eco*RI*-Sca*I fragments and 3′ flanking 2.5 kb *Kpn*I*-Xho*I fragments. The targeting vector was linearized with *Not*I and electroporated into TC1 ES cells (derived from 129S6/SvEvTac mice). G418-resistant ES cell clones were screened for homologous recombination events by Southern blot analysis with 5′ and 3′ external probes. ES cell clones of the two different mutant *Boc* alleles generated by the target vector (see Results) were used to generate chimeric males by injection into C57BL/6 blastocysts, and germline transmission from two chimeric males per clone was confirmed by coat color and Southern blot analysis. These *Boc^+/−^* mice on a mixed background were placed on a B6 background by back-crossing with wild-type B6 mice for six generations. Each *Boc* allele was placed directly onto the 129 background by crossing chimeric males with strain 129 females and screening progeny by Southern blotting. The phenotypes observed from intercrosses of strain 129 heterozygotes of each allele were similar, so the two alleles were used interchangeably in this report.

*Cdo^+/lacZ^*^-^*^1^* (also known as *Cdon^tm1Rsk^*) mice on a 129 background, described previously ([@b9-0040368]; [@b56-0040368]), were crossed with *Boc^+/−^* mice of the same background to generate double heterozygotes; these latter animals were intercrossed and offspring analyzed. All mice were genotyped by PCR analysis of genomic DNA isolated from tail biopsies performed at P9 or P10. *Cdo* genotyping was as described ([@b56-0040368]). *Boc* genotyping was with a three-primer PCR: 5′-AGAACGAGATCA-GCAGCCTCTGTTCC-3′ (forward primer, mutant alleles), 5′-GGAGCCACCATGGATGAACGTGACTTGGCG-3′ (forward primer, wild-type allele), and 5′-GCTATGACAAACAGCATA-GGGTAGGGA-3′ (reverse primer, wild-type and mutant alleles). For timed matings, noon of the plug date was designated E0.5. Visceral yolk sac DNA was used for embryo genotyping.

Southern and western blot analyses
----------------------------------

Genomic DNA was isolated, digested and Southern blotted from ES cell clones, tail tips and visceral yolk sacs by standard procedures. Protein extracts were isolated from the head region of E13.5 embryos for western blot analysis as previously described ([@b9-0040368]), with an anti-Boc antibody (R&D Systems).

Histology, alkaline phosphatase staining, in situ hybridization, qRT-PCR and skeletal analysis
----------------------------------------------------------------------------------------------

Embryos for histology were dissected into 4% paraformaldehyde in phosphate-buffered saline (PBS) and fixed overnight. After dehydration, embryos were embedded in paraffin and sectioned at 8 *μ*m. Hematoxylin and eosin staining was performed by standard protocols as described ([@b9-0040368]). Briefly, after dewaxing in xylene and rehydrating in graded ethanol, slides were stained with Harris' Hematoxylin (Fisher SH26) for 1 minute and washed in running tap water for 20 minutes. This was followed by differentiation in acid alcohol (1% HCl in 70% ethanol) and blueing in Scott's tap water substitute (0.2% Na~2~CO~3~, 1% MgSO~4~). The slides were then counterstained in alcoholic eosin (Fisher SE22) supplemented with glacial acetic acid for 4 minutes. Finally, slides were dehydrated through graded ethanol and xylene and mounted in Cytoseal-60 (Richard-Allan Scientific).

For alkaline phosphatase staining, embryos were dissected in PBS and fixed in 2% paraformaldehyde and 0.2% glutaraldehyde in PBS for 50 minutes at 4°C followed by fixation in 0.2% glutaraldehyde, 0.02% NP-40, and 0.01% sodium deoxycholate in PBS for 60 minutes at 4°C. Embryos were rinsed in PBS and then incubated in PBS at 72°C for 30 minutes to inactivate endogenous alkaline phosphatases. The embryos were then washed in NTM buffer (100 mM NaCl and 50 mM MgCl~2~ in 100 mM Tris-HCl, pH 9.5) for 10 minutes and stained with BM purple alkaline phosphatase substrate (Roche).

For whole-mount in situ hybridization, embryos were dissected and fixed in 4% paraformaldehyde in PBS at 4°C overnight and processed for RNA in situ hybridization as previously described ([@b37-0040368]) with probes against *Shh*, *Fgf8*, *Gli1* and *Ptch1*. For thin-section in situ hybridization, embryos were embedded in paraffin after fixation and dehydration and sectioned at 8 *μ*m. The sections were then dewaxed, rehydrated and processed for RNA in situ hybridization as previously described ([@b37-0040368]) with probes against *Ptch1* and *Nkx2.1*.

qRT-PCR analysis of *Shh*, *Fgf8* and *Nkx2.1* expression was performed on E10.5 control (*Cdo*^+/+^*;Boc^+/−^, Cdo^+/−^;Boc*^+/+^ or *Cdo^+/−^;Boc^+/−^*) and *Cdo^--/−^;Boc^--/−^* embryos. Embryonic heads were dissected out and transferred into 0.4 ml Trizol. cDNA was synthesized from total RNA using SuperScript III First Strand Synthesis System (Invitrogen). qPCR was performed using PerfeCta SYBR Green FastMix for iQ (Quanta Biosciences) with a Bio-Rad iCycler iQ5. Data were normalized to *Gapdh* levels and presented as fold change over control. qPCR primers for *Gapdh*, *Shh* and *Fgf8* were from the Harvard PrimerBank (Primerbank Ids: 6679937a1, 21617861a1 and 22094093a1, respectively) ([@b49-0040368]). qPCR primers for *Nkx2.1* were from a published paper ([@b57-0040368]).

For skeletal analysis, E18.5 embryos were dissected and fixed in 95% ethanol for 1--2 hours before removing skin, adipose tissue and internal organs, except the brain. The embryos were then further fixed for 3--5 days in 95% ethanol followed by treatment with acetone for 3 days. Embryos were then rinsed with water, stained for cartilage with Alcian Blue staining solution (30 mg Alcian Blue in 20 ml glacial acetic acid and 80 ml of 95% ethanol) for 24 hours, rinsed twice with 95% ethanol, and incubated in 95% ethanol for 2 days. The embryos were then treated with 1% KOH for 1 hour to dissolve soft tissues before staining for bone with Alizarin Red staining solution (0.075% Alizarin Red in 1% KOH) for 5 hours. Finally, the resulting skeletal preparations were passed through graded glycerol in 1% KOH to clear any remaining tissue.

###### TRANSLATIONAL IMPACT

### Clinical issue

Holoprosencephaly (HPE), one of the most common human birth defects, is caused by a failure to form the midline of the forebrain and/or midface. Its clinical presentation is extremely variable, ranging from alobar HPE, where there is a complete failure to divide the forebrain into left and right hemispheres, to the milder lobar HPE, and finally to microforms of HPE in which there are facial midline abnormalities but no brain malformation. HPE is probably caused by both genetic and environmental changes, with the former often associated with heterozygous mutations in components or regulators of the sonic hedgehog (SHH) signaling pathway. The wide spectrum of abnormalities seen in carriers of SHH pathway mutations, ranging from no clinical manifestation, to alobar HPE, suggest that other genes, (so-called 'silent modifiers'), as yet unidentified, might have a role in determining HPE penetrance. This notion is supported by mouse experiments: mice in which the *Cdo* gene, a modifier of SHH signaling, has been knocked out, have different degrees of HPE depending on their genetic background.

### Results

To test whether the effects of *Cdo* mutation can be modified by other silent mutations, the authors constructed mice with a null mutation of *Boc*, a close relative of *Cdo*. Mice lacking Boc do not have HPE; however, *Cdo;Boc* double mutants on a normally *Cdo*-resistant genetic background (129S6) have lobar HPE with strong craniofacial midline anomalies and defects in Shh target gene expression in the developing forebrain. These phenotypes are *Boc* dosage-sensitive; *Cdo^--/−^;Boc^+/−^* embryos show similar phenotypes to *Cdo^--/−^;Boc^--/−^*embryos, except they are milder and occur with lower penetrance. *Boc* is therefore a silent HPE modifier gene in mice.

### Implications and future directions

As HPE is thought to arise from a complex interplay of developmental, genetic and environmental factors, it has been difficult to study in animal models. 129S6.*Cdo^--/−^* mice might be useful for testing the multifactorial hypothesis of human HPE and for identifying additional cooperating factors, both genetic and environmental. Genes that modify the phenotypic severity of HPE in mice might do the same in humans, and the identification of cross-species silent modifiers will aid in the counseling of individuals with genetic predisposition to HPE.
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